Fact based stock research
Realcan Pharmaceutical (SZSE:002589)

CNE1000013X5

Realcan Pharmaceutical stock research in summary

Realcan Pharmaceutical shares have a market-typical stock price level. While they are safely financed, they are poor value, and show below average growth. We recommend evaluating whether the future of the company Realcan Pharmaceutical is typical for this industry which the market average price level of the shares suggests. If you believe that the future of the company is above average, that could be an argument for buying the shares and vice versa.

Latest Obermatt Ranks


Value Rank	44
Growth Rank	7
Safety Rank	100
Combined Rank	64

Country	China
Industry	Health Care Distributors
Index
Size class	X-Large

June 26, 2020. Stock data may be delayed. Login to get the most recent research.

Add to Watchlist

Filter Similar Stocks

Similar Top 10

Google: Realcan Pharmaceutical

News	Videos
Wikipedia about Realcan Pharmaceutical	Management
Employee Satisfaction	Customer Satisfaction

Research History: Realcan Pharmaceutical

RESEARCH HISTORY	2017	2018	2019	2020
VALUE
VALUE	32	75	64	44
GROWTH
GROWTH	100	82	39	7
SAFETY
SAFETY	100	48	78	100
COMBINED
COMBINED	83	82	80	64

Last update of Combined Rank: 26-Jun-2020. Financial reporting date used for calculating ranks: 31-Mar-2020. Stock research history is based on the Obermatt Method. The higher the rank, the better Realcan Pharmaceutical is in the corresponding investment strategy.

Value Metrics in Detail

VALUE METRICS	2017	2018	2019	2020
PRICE VS. REVENUES (P/S)
PRICE VS. REVENUES (P/S)	68	81	87	83
PRICE VS. PROFITS (P/E)
PRICE VS. PROFITS (P/E)	29	88	57	2
PRICE VS. CAPITAL (Market-to-Book)
PRICE VS. CAPITAL (Market-to-Book)	40	82	76	76
DIVIDEND YIELD
DIVIDEND YIELD	22	28	28	34
CONSOLIDATED RANK: VALUE
CONSOLIDATED RANK: VALUE	32	75	64	44

Last update of Value Rank: 26-Jun-2020. Stock analysis on value ratios: The higher the rank, the lower the value ratio of Realcan Pharmaceutical; except for dividend yield where the rank is higher, the higher the yield.

Growth Metrics in Detail

GROWTH METRICS	2017	2018	2019	2020
REVENUE GROWTH
REVENUE GROWTH	89	96	70	15
PROFIT GROWTH
PROFIT GROWTH	87	89	37	36
STOCK RETURNS
STOCK RETURNS	52	32	18	10
CONSOLIDATED RANK: GROWTH
CONSOLIDATED RANK: GROWTH	100	82	39	7

Last update of Growth Rank: 31-Mar-2020. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Realcan Pharmaceutical.

Safety Metrics in Detail

SAFETY METRICS	2017	2018	2019	2020
LEVERAGE
LEVERAGE	44	6	44	53
REFINANCING
REFINANCING	90	96	98	98
LIQUIDITY
LIQUIDITY	40	45	71	96
CONSOLIDATED RANK: SAFETY
CONSOLIDATED RANK: SAFETY	100	48	78	100

Last update of Safety Rank: 19-Jun-2020. Stock analysis on safety metrics: The higher the rank, the lower the leverage of Realcan Pharmaceutical and the more cash is available to service its debt.

Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Realcan Pharmaceutical from June 26, 2020.

We invest in our stock tips ourselves and openly publish the returns of our portfolio. That's how much we believe in our stock research. Subscribe to the top 10 stocks for 100 markets conveniently by e-mail.